Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | TACR1 | P25103 | 2/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CFTR | P13569 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600421 | 0.85 | MEN1 (0.40) | IDO1SLC6A4SLC6A3SLC6A2TACR1 | |
| SCHEMBL1600954 | 0.84 | SLC6A4 (0.34) | IDO1SLC6A4SLC6A3SLC6A2TACR1 | |
| SCHEMBL1600958 | 0.84 | FFAR4 (0.35) | TACR1CFTR | |
| SCHEMBL1600500 | 0.81 | TACR1 (0.44) | TACR1 | |
| SCHEMBL1599512 | 0.79 | ALOX15 (0.39) | IDO1SLC6A4SLC6A3SLC6A2CETP | |
| SCHEMBL1600303 | 0.79 | ALOX15 (0.39) | IDO1SLC6A4SLC6A3SLC6A2CETP | |
| SCHEMBL3949919 | 0.79 | SLC6A4 (0.36) | IDO1SLC6A4SLC6A3SLC6A2TACR1 | |
| SCHEMBL1601207 | 0.79 | SLC6A4 (0.36) | IDO1SLC6A4SLC6A3SLC6A2TACR1 | |
| SCHEMBL1600369 | 0.78 | SLC6A4 (0.34) | IDO1SLC6A4SLC6A3SLC6A2MEN1 | |
| SCHEMBL1601202 | 0.78 | ALOX15 (0.40) | IDO1SLC6A4SLC6A3SLC6A2CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919506-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919506-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1996564-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | Pfizer Products Incorporated (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007105050-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | APOB, LDLR, CETP | IDO1 910/4885SLC6A4 1459/4885SLC6A3 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.